High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Shares of Teladoc Health fell more than 25% Thursday after the telehealth company missed second-quarter revenue expectations and cut its full-year sales forecast. The pain is concentrated in BetterHelp, Teladoc's therapy and psychiatry platform, where revenue fell 12% to $212.6 million. Teladoc has pushed BetterHelp users toward insurance-covered therapy instead of cash-pay sessions.
Teladoc Health (TDOC) reported a Q2 loss late Wednesday of $0.21 per diluted share, wider than a los
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.